All In Biotech

Drug Trial Radar · NCT01714713

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to Two Doses of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro-cognitive Treatment in Subjects With Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy

Last checked: Nov 20, 2026Latest source record: May 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 830 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

830

Actual

Start

Jun 2013

Primary completion

Oct 2015

Study completion Oct 2015

Sponsor

Lead sponsor
FORUM Pharmaceuticals IncIndustry
Sponsor type
Industry
Collaborators
Syneos Health
First posted
Oct 26, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to further investigate the safety of prolonged exposure to EVP-6124 in subjects with Schizophrenia receiving a stable dose of an atypical antipsychotic who completed double-blind treatment on studies EVP-6124-015 and EVP-6124-016.

Conditions

  • Schizophrenia
  • Impaired Cognition

Interventions

  • EVP-6124Drug

    Arm 1, 2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability of EVP-6124 or Placebo in Subjects with SchizophreniaTime frame: Baseline through Day 182 or Early Termination

Locations

128 sites in 16 countries. Site status is shown where the registry gives one.

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Anaheim, California

  • Site not named

    Bellflower, California

  • Site not named

    Cerritos, California

  • Site not named

    Chino, California

  • Site not named

    Costa Mesa, California

  • Site not named

    Culver City, California

  • Site not named

    Downey, California

  • Site not named

    Escondido, California

  • Site not named

    Garden Grove, California

  • Site not named

    Glendale, California

  • Site not named

    Los Angeles, California

  • Site not named

    Mesa, California

  • Site not named

    Norwalk, California

  • Site not named

    Oakland, California

  • Site not named

    Oceanside, California

  • Site not named

    Orange, California

  • Site not named

    Riverside, California

  • Site not named

    San Diego, California

  • Site not named

    San Gabriel, California

  • Site not named

    Santa Ana, California

  • Site not named

    Sherman Oaks, California

  • Site not named

    Torrance, California

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Lauderhill, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami Springs, Florida

  • Site not named

    North Miami, Florida

  • Site not named

    Oakland Park, Florida

  • Site not named

    Orange City, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Marietta, Georgia

  • Site not named

    Smyrna, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Oak Brook, Illinois

  • Site not named

    Oak Park, Illinois

  • Site not named

    Wichita, Kansas

  • Site not named

    Lake Charles, Louisiana

  • Site not named

    Shreveport, Louisiana

Showing 40 of 128 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.